News | August 19, 2024
Aptar’s nasal unidose system delivers FDA-approved neffy
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
These gummies are specially formulated for both kids and adults to nourish the eyes and promote optimal vision development
Access to breast milk for sick newborns admitted in intensive care units plays a lifesaving role
Campaign launched to spread awareness regarding dengue prevention and control
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Subscribe To Our Newsletter & Stay Updated
